NuPathe Stock Price, News & Analysis (NASDAQ:PATH)

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E Ratio-2.45
Dividend YieldN/A

About NuPathe (NASDAQ:PATH)

NuPathe, Inc. develops therapeutics for diseases of the central nervous system including neurological and psychiatric disorders. The Companys products are NP201 for the continuous symptomatic treatment of Parkinson's disease and NP202 for the long-term treatment of schizophrenia and bipolar disorder. The Company completed a pivotal Phase III clinical trial for Zelrix, an active, single-use transdermal sumatriptan patch for the treatment of acute migraine.

Receive PATH News and Ratings via Email

Sign-up to receive the latest news and ratings for PATH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E Ratio-2.45089285714286
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding SharesN/A

NuPathe (NASDAQ:PATH) Frequently Asked Questions

What is NuPathe's stock symbol?

NuPathe trades on the NASDAQ under the ticker symbol "PATH."

Who are some of NuPathe's key competitors?

How do I buy NuPathe stock?

Shares of NuPathe can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact NuPathe?

NuPathe's mailing address is 7 Great Valley Pkwy Ste 300, MALVERN, PA 19355-1425, United States. The healthcare company can be reached via phone at +1-610-2320800.

MarketBeat Community Rating for NuPathe (PATH)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  36 (Vote Outperform)
Underperform Votes:  47 (Vote Underperform)
Total Votes:  83
MarketBeat's community ratings are surveys of what our community members think about NuPathe and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

NuPathe (NASDAQ:PATH) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/AN/A
Consensus Rating Score: N/AN/AN/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

NuPathe (NASDAQ:PATH) Consensus Price Target History

Price Target History for NuPathe (NASDAQ:PATH)

NuPathe (NASDAQ:PATH) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/28/2016WedbushDowngradeOutperform -> Neutral$8.00 -> $5.00N/AView Rating Details
(Data available from 2/24/2016 forward)


NuPathe (NASDAQ:PATH) Earnings History and Estimates Chart

Earnings by Quarter for NuPathe (NASDAQ:PATH)

NuPathe (NASDAQ PATH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2013Q3($0.20)($0.25)ViewListenView Earnings Details
8/8/2013Q2 2013($0.20)($0.16)ViewN/AView Earnings Details
5/14/2013Q1 2013($0.17)($0.68)ViewN/AView Earnings Details
3/26/2013Q4 2012($0.33)($1.16)ViewN/AView Earnings Details
11/12/2012Q312($0.38)($0.42)ViewN/AView Earnings Details
8/14/2012Q2 2012($0.41)($0.42)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.41)($0.43)ViewN/AView Earnings Details
3/20/2012Q4 2011($0.50)($0.38)ViewN/AView Earnings Details
11/14/2011Q3 2011($0.51)($0.51)ViewN/AView Earnings Details
8/15/2011Q2 2011($0.46)($0.44)ViewN/AView Earnings Details
5/10/2011Q1 2011($0.47)($0.26)ViewN/AView Earnings Details
3/18/2011Q4 2010($0.46)($0.42)ViewN/AView Earnings Details
11/11/2010Q3 2010($0.55)($0.81)ViewN/AView Earnings Details
9/14/2010Q2 2010($17.42)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


NuPathe (NASDAQ:PATH) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for NuPathe (NASDAQ:PATH)

No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for NuPathe (NASDAQ PATH)

No insider trades for this company have been tracked by


NuPathe (NASDAQ PATH) News Headlines


SEC Filings

NuPathe (NASDAQ:PATH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


NuPathe (NASDAQ:PATH) Income Statement, Balance Sheet and Cash Flow Statement


NuPathe (NASDAQ PATH) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.